Overview

A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)

Status:
Recruiting

Trial end date:
2022-07-15

Target enrollment:

Participant gender:

Summary

The Sponsor is developing the test medicine, Capivasertib, for the potential treatment of primary breast and prostate cancer. This two-part healthy volunteer study will try to identify the absolute bioavailability (amount of the test medicine that enters the blood stream), mass balance recovery (how much radioactivity can be recovered from the urine and faeces) and the rates and routes of elimination of the test medicine.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Quotient Sciences